Search

Your search keyword '"Jung, Young Kul"' showing total 16 results
Start Over Author "Jung, Young Kul" Journal gut and liver
16 results on '"Jung, Young Kul"'

4. Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma

Author

Lee, Han Ah, primary, Lee, Young-Sun, additional, Kim, Beom Kyung, additional, Jung, Young Kul, additional, Kim, Seung Up, additional, Park, Jun Yong, additional, Kim, Ji Hoon, additional, An, Hyunggin, additional, Kim, Do Young, additional, Yim, Hyung Joon, additional, Ahn, Sang Hoon, additional, Yeon, Jong Eun, additional, Byun, Kwan Soo, additional, Han, Kwang-Hyub, additional, Um, Soon Ho, additional, and Seo, Yeon Seok, additional

Published
2021
Full Text
View/download PDF

5. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Author

Ahn, Young Eun, primary, Suh, Sang Jun, additional, Yim, Hyung Joon, additional, Seo, Yeon Seok, additional, Yoon, Eileen L., additional, Kim, Tae Hyung, additional, Lee, Young Sun, additional, Yim, Sun Young, additional, Kim, Hae Rim, additional, Kang, Seong Hee, additional, Jung, Young Kul, additional, Kim, Ji Hoon, additional, Yeon, Jong Eun, additional, Um, Soon Ho, additional, and Byun, Kwan Soo, additional

Published
2021
Full Text
View/download PDF

6. Evaluation of Treatment Response after Endoscopic Variceal Obturation with Abdominal Computed Tomography

Author

Lee, Han Ah, primary, Goh, Hyun Gil, additional, Kim, Tae Hyung, additional, Lee, Young-Sun, additional, Suh, Sang Jun, additional, Jung, Young Kul, additional, Choi, Hyuk Soon, additional, Kim, Eun Sun, additional, Kim, Ji Hoon, additional, An, Hyunggin, additional, Seo, Yeon Seok, additional, Yim, Hyung Joon, additional, Cho, Sung Bum, additional, Jeen, Yoon Tae, additional, Yeon, Jong Eun, additional, Chun, Hoon Jai, additional, Byun, Kwan Soo, additional, Um, Soon Ho, additional, and Kim, Chang Duck, additional

Published
2020
Full Text
View/download PDF

7. Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms

Author

Lee, Young-Sun, primary, Seo, Yeon Seok, additional, Kim, Ji Hoon, additional, Lee, Juneyoung, additional, Kim, Hae Rim, additional, Yoo, Yang Jae, additional, Kim, Tae Suk, additional, Kang, Seong Hee, additional, Suh, Sang Jun, additional, Joo, Moon Kyung, additional, Jung, Young Kul, additional, Lee, Beom Jae, additional, Yim, Hyung Joon, additional, Yeon, Jong Eun, additional, Kim, Jae Seon, additional, Park, Jong-Jae, additional, Um, Soon Ho, additional, Bak, Young-Tae, additional, and Byun, Kwan Soo, additional

Published
2018
Full Text
View/download PDF

8. The Efficacy and Safety of Peginterferon-α-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting

Author

Kwon, Jung Hyun, Kim, Young Seok, Kim, Sang Gyune, Jang, Jeong Won, Kim, Tae Hun, Jung, Young Kul, and Kwon, Oh Sang

Subjects
Liver, Pancreas and Biliary Tract, virus diseases, Original Article, Peginterferon, Chronic hepatitis B, Asian continental ancestry group
Abstract

Background/Aims Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon α-2a therapy. The efficacy of and compliance to peginterferon α-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods Hepatitis B patients treated with peginterferon α-2a from 2008 to 2011 at four university hospitals were consecutively enrolled. Results Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1±15.2 weeks. In 26.1% of patients, treatment was discontinued due to insufficient antiviral effects and adverse events. At 24 weeks after treatment, 10/42 (23.8%) HBeAg-positive patients achieved both HBV DNA suppression to 2×106 IU/mL. Conclusions Peginterferon α-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals, but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies.

Published
2013

14. Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B

Author

Jung, Young Kul, primary, Yeon, Jong Eun, additional, Han, Woo Sik, additional, Kim, Ji Hoon, additional, Kim, Jeong Han, additional, Park, Jong-Jae, additional, Kim, Jae Seon, additional, Bak, Young-Tae, additional, Yoo, Wangdon, additional, Hong, Sun Pyo, additional, Kim, Soo-Ok, additional, Kwon, So Young, additional, Byun, Kwan Soo, additional, and Lee, Chang Hong, additional

Published
2010
Full Text
View/download PDF

15. Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B.

Author

Kim TH, Kim JH, Yim HJ, Seo YS, Yim SY, Lee YS, Jung YK, Yeon JE, Um SH, and Byun KS

Subjects
Humans, Tenofovir therapeutic use, Retrospective Studies, Treatment Outcome, Antiviral Agents therapeutic use, Adenine, Alanine, Hepatitis B, Chronic, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy, Guanine analogs & derivatives, Organophosphonates
Abstract

Background/aims: : Besifovir dipivoxil maleate (BSV) and tenofovir alafenamide fumarate (TAF) have been recently approved in Korea as the initial antiviral agents for chronic hepatitis B (CHB). However, the real-world outcome data for these drugs remain limited. Therefore, we conducted a noninferiority analysis using real-world data to compare the clinical outcomes of the two nucleotide analogs in treatment-naïve patients with CHB., Methods: : We retrospectively investigated a cohort of patients with CHB who received BSV or TAF as first-line antiviral agents. The endpoints were virological response (VR) and liver-related clinical outcomes., Results: : A total of 537 patients, consisting of 202 and 335 patients administered BSV and TAF, respectively, were followed up for 42 months. No significant difference was observed between the VRs of the patients from the two groups. The rates of biochemical response, virologic breakthrough, and incidence rates of hepatocellular carcinoma did not differ between the groups. However, the hepatitis B e antigen seroclearance rate was higher and the renal function declined less in the BSV group. Multivariable analysis indicated older age, alcohol abuse, cirrhosis and ascites, and lower serum HBV DNA level to be independently associated with increased hepatocellular carcinoma risk. The 1:1 propensity score-matched analysis with 400 patients showed VR rates of 85.0% and 88.7% in the BSV and TAF group patients, respectively, at 2 years. The absolute value of the 95% confidence interval for the difference (-0.04 to 0.12) satisfied the a priori limit of a noninferiority of 0.15., Conclusions: : BSV is noninferior to TAF in terms of VR, and their clinical outcomes are comparable to CHB.

Published
2024
Full Text
View/download PDF

16. Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.

Author

Cho EY, Yim HJ, Jung YK, Suh SJ, Seo YS, Kim JH, Kim HS, Lee SH, Ahn SH, Lee JI, Jeong SH, Kim JW, Lee JW, Kim IH, Kim HS, Park SJ, Lee JM, and Hwang SG

Subjects
Adenine therapeutic use, Adult, Aged, Arabinofuranosyluracil therapeutic use, Cohort Studies, DNA, Viral blood, Disease Management, Drug Resistance, Viral genetics, Drug Therapy, Combination, Female, Genotype, Guanine therapeutic use, Hepatitis B virus genetics, Hepatitis B, Chronic blood, Hepatitis B, Chronic virology, Humans, Male, Middle Aged, Viral Load, Adenine analogs & derivatives, Antiviral Agents therapeutic use, Arabinofuranosyluracil analogs & derivatives, Guanine analogs & derivatives, Hepatitis B, Chronic drug therapy, Lamivudine therapeutic use, Organophosphonates therapeutic use
Abstract

Background/aims: Data are lacking regarding the management of chronic hepatitis B (CHB) with resistance to clevudine (CLV). This study evaluated the efficacy of different rescue therapies for CLV-resistant CHB., Methods: Patients with CLV-resistant CHB were enrolled in the cohort, and all patients developed virologic breakthrough during CLV therapy and had confirmed-genotypic resistance to CLV (rtM204I mutation) before enrollment., Results: Of the 107 patients, 12 received adefovir (ADV), 21 received a CLV plus ADV combination (CLV+ADV), 34 received a lamivudine plus ADV combination (LAM+ADV), and 40 received entecavir (ETV) therapy for 48 weeks. The CLV+ADV group had the lowest hepatitis B virus (HBV) DNA level (p<0.0001) and showed the greatest reduction of HBV DNA levels from baseline compared to all other groups (p=0.004) at week 48. HBV DNA was undetectable (<70 IU/mL) in 0%, 57.1%, 21.2%, and 27.5% (p=0.003) of the patients in each group, respectively, at week 48. At the end of the study, the mean alanine transaminase (ALT) level, rate of ALT normalization, and rate of hepatitis B envelope antigen loss or seroconversion did not differ between groups., Conclusions: CLV+ADV combination therapy in patients with CLV-resistant CHB more effectively suppresses HBV replication than ETV, ADV, or LAM+ADV therapy.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results